Literature DB >> 24724070

Acute myeloid leukemia arising from chronic myelomonocytic leukemia during hypomethylating therapy.

Pasquale Niscola1, Andrea Tendas1, Laura Scaramucci1, Marco Giovannini1, Daniela Piccioni1, Paolo de Fabritiis1.   

Abstract

Entities:  

Year:  2014        PMID： 24724070      PMCID： PMC3974962          DOI： 10.5045/br.2014.49.1.65

Source DB:  PubMed          Journal:  Blood Res        ISSN： 2287-979X


× No keyword cloud information.
  9 in total

1.  Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.

Authors:  Francesco Onida; Hagop M Kantarjian; Terry L Smith; Greg Ball; Michael J Keating; Elihu H Estey; Armand B Glassman; Maher Albitar; Monica I Kwari; Miloslav Beran
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far?

Authors:  Massimo Breccia; Maria Teresa Voso; Giuliana Alimena
Journal:  Leuk Res       Date:  2012-11-20       Impact factor: 3.156

3.  High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study.

Authors:  Luana Fianchi; Marianna Criscuolo; Massimo Breccia; Luca Maurillo; Flavia Salvi; Pellegrino Musto; Giovanna Mansueto; Gianluca Gaidano; Carlo Finelli; Antonietta Aloe-Spiriti; Valeria Santini; Mariangelo Greco; Stefan Hohaus; Giuseppe Leone; Maria Teresa Voso
Journal:  Leuk Lymphoma       Date:  2012-08-30

Review 4.  Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review.

Authors:  Michael Thorpe; Ana Montalvão; Francesca Pierdomenico; Filipa Moita; António Almeida
Journal:  Leuk Res       Date:  2012-05-17       Impact factor: 3.156

5.  Activity of azacitidine in chronic myelomonocytic leukemia.

Authors:  Rubens Costa; Haifaa Abdulhaq; Bushra Haq; Richard K Shadduck; Joan Latsko; Mazen Zenati; Folefac D Atem; James M Rossetti; Entezam A Sahovic; John Lister
Journal:  Cancer       Date:  2010-12-23       Impact factor: 6.860

Review 6.  Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.

Authors:  Sameer A Parikh; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2012-06       Impact factor: 10.047

7.  Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

Authors:  Yoo-Jin Kim; Jun Ho Jang; Jae-Yong Kwak; Je-Hwan Lee; Hyeoung-Joon Kim
Journal:  Blood Res       Date:  2013-06-25

8.  Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).

Authors:  P W Wijermans; B Rüter; M R Baer; J L Slack; H I Saba; M Lübbert
Journal:  Leuk Res       Date:  2007-09-18       Impact factor: 3.156

9.  Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia.

Authors:  Elizabeth L Courville; Yue Wu; Jihen Kourda; Christine G Roth; Jillian Brockmann; Alona Muzikansky; Amir T Fathi; Laurence de Leval; Attilio Orazi; Robert P Hasserjian
Journal:  Mod Pathol       Date:  2013-01-11       Impact factor: 7.842
  9 in total
  2 in total

1.  Successful long-term treatment with azacitidine in patient with chronic myelomonocytic leukemia.

Authors:  Luka Čemažar; Helena Podgornik; Njetočka Gredelj Šimec; Samo Zver
Journal:  Hematol Rep       Date:  2020-12-02

Review 2.  Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?

Authors:  Konstantinos Liapis; Ioannis Kotsianidis
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.